Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/053245external-prioritypatent/WO2009115572A2/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2010000427A1publicationCriticalpatent/TN2010000427A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
TNP2010000427A2009-03-192010-09-17Novel heterocyclic compounds and uses thereof
TN2010000427A1
(en)
Compounds derived from substituted carboxyamide heterocycles, ar antagonist; pharmaceutical composition comprising them; and use in the treatment of prostate cancer.